Kanada - francuski - Health Canada

nordic selfcare institute p-technologies int'l (pti) inc. - acide ascorbique; zinc (gluconate de zinc) - comprimé - 24mg; 2mg - acide ascorbique 24mg; zinc (gluconate de zinc) 2mg - vitamins & minerals

Belgia - francuski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bavarian nordic a.s. - virus rabique inactivé >= 2,5 ui - poudre et solvant pour solution injectable en seringue pré-remplie - virus rabique inactivé - rabies, inactivated, whole virus

Tunezja - francuski - Ministère de la Santé, Direction de l'inspection Pharmaceutique

nordic pharma - hyaluronate de sodium - solution injectable - 20 mg/2ml - muscle et squelette - autres medicaments en cas de troubles du systeme m - - comme agent de remplacement du liquide synovial après une arthrocentèse. - en améliorant les propriétés rhéologiques du liquide synovial, suplasyn a montré, dans l'arthrose, une action bénéfique sur les symptômes douloureux et sur la fonction mécanique des articulations.

Unia Europejska - francuski - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, la souche cvd 103-hgr, en direct - choléra - vaccins - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. ce vaccin doit être utilisé conformément aux recommandations officielles.

Szwajcaria - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

bavarian nordic switzerland ag - virus vaccinia ankara modificatus vivus attenuatum - suspension injectable - virus vaccinia ankara modificatus vivus attenuatum ≥ 50 mio. u., trometamolum, natrii chloridum corresp. natrium 1.6 mg, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen durch pocken-, affenpocken- und vacciniaviren hervorgerufene erkrankungen - les vaccins

Unia Europejska - francuski - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hémoglobinurie paroxystique - immunosuppresseurs sélectifs - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Unia Europejska - francuski - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - néoplasmes du sein - agents antinéoplasiques - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Francja - francuski - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

medipha sante - vinorelbine base - solution - 10 mg - composition pour 1 ml de solution injectable > vinorelbine base : 10 mg . sous forme de : tartrate de vinorelbine - vinca-alcaloides et analogues (l antinéoplasiques et immunomodulateurs)

Francja - francuski - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

medipha sante - vinorelbine base - solution - 10 mg - composition pour 1 ml de solution injectable > vinorelbine base : 10 mg . sous forme de : tartrate de vinorelbine - vinca-alcaloides et analogues (l antinéoplasiques et immunomodulateurs)

Francja - francuski - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

medipha sante - vinorelbine base - solution - 10 mg - composition pour 1 ml de solution injectable > vinorelbine base : 10 mg . sous forme de : tartrate de vinorelbine - vinca-alcaloides et analogues (l antinéoplasiques et immunomodulateurs)